ArticleMetabolic brain disease2026
Exercise-induced GPLD1 is associated with neuroprotection and improvement of hippocampal dysfunction in an Alzheimer's disease model.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the therapeutic potential of exercise training and the associated role of Glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) in an experimental Alzheimer’s disease (AD) model. Using a D-galactose/AlCl3 induced rodent model, we evaluated behavioral impairments, AD pathological markers, and the expression of key signaling pathways linked to neurodegeneration and neuroprotection, alongside and neurotrophic factors. Male rats were divided into Control, AD, Exercise, and AD + Exercise groups. The AD model exhibited significant deficits in locomotor activity, exploratory behavior, and spatial learning/memory, alongside elevated hippocampal Aβ1–42, tau protein, AChE activity. This was accompanied by overactivation of pathways implicated in neuroinflammation and pathology (NF-κB, mTOR, GSK-3β), and downregulation of pathways crucial for neuronal survival and plasticity (Wnt3a/β-catenin, PI3K/Akt), in addition to reduced GPLD1 and BDNF. Exercise intervention significantly ameliorated these behavioral deficits, increased hippocampal BDNF, GPLD1, and restored activity in pro-survival pathways (Wnt3a/β-catenin, PI3K/Akt) while reducing AD pathology markers. Notably, the AD + Exercise group demonstrated substantial recovery in most parameters compared to the AD group. Furthermore, plasma and liver GPLD1 levels were markedly upregulated by exercise. These findings collectively suggest that exercise training is associated with robust neuroprotection, correlating with systemic GPLD1 upregulation, and highlights the GPLD1 axis for future therapeutic investigation in AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.